Bank Julius Baer & Co. Ltd, Zurich Myovant Sciences Ltd. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$11.38 - $16.4 $12,290 - $17,712	-1,080 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$18.94 - $26.99 $340 - $485	-18 Reduced 1.64%	1,080 $24,000
Q2 2021 Jul 23, 2021	BUY	$17.07 - $24.56 $2,304 - $3,315	135 Added 14.02%	1,098 $25,000
Q1 2021 May 10, 2021	SELL	$20.46 - $25.18 $2,516 - $3,097	-123 Reduced 11.33%	963 $20,000
Q4 2020 Feb 24, 2021	BUY	$13.8 - $27.62 $82 - $165	6 Added 0.56%	1,086 $30,000
Q4 2020 Feb 12, 2021	BUY	$13.8 - $27.62 $14,904 - $29,829	1,080 New	1,080 $30,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.